VENT 03
Alternative Names: Cyclic GMP-AMP synthase (cGAS) inhibitor program - Ventus Therapeutics; VENT-03Latest Information Update: 09 Jan 2024
At a glance
- Originator Ventus Therapeutics
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action CGAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Immunological disorders; Inflammation; Skin disorders
Most Recent Events
- 03 Jan 2024 Phase-I clinical trials in Inflammation (In volunteers) (PO)
- 03 Jan 2024 Phase-I clinical trials in Immunological disorders (In volunteers) (PO)
- 03 Jan 2024 Phase-I clinical trials in Skin disorders (In volunteers) (PO)